PCNA and prostate cancer: Herein, we report the potential of CDKN1, FDXR, SESN1 and PCNA packaged as a 4-gene signature as a potential radiosensitivity biomarker and validated using the G2 chromosomal radiosensitivity profile of individual samples of both the prostate cancer and healthy donor cohort exposed to low doses of IR.